Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Canada Gives $440K to PGx-Based Pediatric Drug Toxicity Study

NEW YORK (GenomeWeb News) — Pfizer Canada has given CA$500,000 ($440,000) to a Canadian research project studying the pharmacogenomics of pediatric drug toxicity, the company said today.
The project, Genotype-Specific Approaches to Therapy in Childhood initiative, or GATC, plans to study DNA from children who have experienced adverse drug reactions in hopes of identifying biomarkers linked to severe drug toxicity.
The goal of the project is to create a diagnostic that can help predict when ADRs might happen, and to generate a pediatric genetic profile that results in dosing recommendations for “different treatments.” 
The program will compare DNA and plasma samples from children who have experienced ADRs against those who have not, and will work with a network of 2,300 pediatricians and 10 hospitals. 
GATC is being led by Bruce Carleton and Michael Hayden. Carleton is director of Pharmaceutical Outcomes Research at the Children’s and Women’s Health Center at the University of British Columbia, Michael Hayden is director of the Center for Molecular Medicine and Therapeutics.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.